作者：柳天宇1，张昊芃1，魏英1，戴萱1，寇涛1，何坤2

单位：1.西南医科大学 临床医学院，四川 泸州 646000； 2.西南医科大学附属医院 临床医学研究中心，四川 泸州 646000

Authors:  Liu Tianyu1, Zhang Haopeng1, Wei Ying1, Dai Xuan1, Kou Tao1, He Kun2

Unit: 1. School of Clinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan, China； 2. Clinical Medicine Research Center, Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China

摘要：

目的 通过文献计量学和可视化分析，探讨2018年至2022年全球范围内免疫检查点抑制剂治疗肝细胞癌研究领域中的热点与趋势。方法 选用Web of Science核心数据库，获取肝细胞癌研究中免疫检查点抑制剂相关的1875篇文献，采用CiteSpace 从作者、机构、国家、关键词、文献等方面进行统计和可视化分析。结果 文章数量及被引量逐年增加。本研究中最活跃的国家和机构分别是中国和中山大学。最活跃和被引用最多作者分别是Kudo Masatoshi和El-Khoueiry AB。共同引用网络中关键节点的聚类和时间线视图表明免疫检查点抑制剂治疗肝细胞癌领域的转变。程序性细胞死亡配体1（programmed cell death ligand 1，PD-L1）表达和伊匹木单抗（ipilimumab）是研究的重点。树突状细胞相关研究一直持续爆发。目前该领域的兴趣主要转向患者治疗后的生存期评价、Ⅲ期临床试验、联合治疗研究等方面。结论 免疫检查点抑制剂的联合治疗是目前的前沿研究，具有远阔前景，未来主要研究方向可能集中在联合治疗、疗效和安全性评价、肿瘤微环境和新型预测生物标志物的开发上。

关键词： CiteSpace；肝细胞癌；免疫检查点抑制剂；可视化分析

Abstract：

Objective  To analyze the hotspots and trends in the field of immune checkpoint inhibitors for hepatocellular carcinoma research globally from 2018 -2022 through bibliometric and visual analysis. Method The Web of Science core database was selected to obtain 1875 papers related to immune checkpoint inhibitors in hepatocellular carcinoma research, and CitesSpace was used for statistical and visual analysis in terms of authors, institutions, countries, keywords, and literature. Result The number of articles and the number of citations increased each year. The most active countries or regions and institutions in this study were China and Sun Yat-sen University, respectively. The most active and most cited authors were Kudo, Masatoshi and El-Khoueiry AB, respectively. The aggregation and identification of key nodes in the co-citation network indicate a shift in the field of hepatocellular carcinoma immunotherapy. Initially, PD-L1 expression and ipilimumab were the focus of studies. Dendritic cells have continued to explode. Recently, the interest in the field has shifted mainly to patients post-treatment survival, phrase Ⅲ, and combination therapy. Conclusion Combination therapy with immune checkpoint inhibitors is the current frontier research with far -reaching prospects, and the main future research directions may focus on combination therapy, efficacy and safety, tumor microenvironment, and the development of novel predictive biomarkers.

Key Words:  CiteSpace; Hepatocellular carcinoma; Immune checkpoint inhibitors; Visualization analysis